Swedish Orphan Biovitrum

Overview

• Industrypharmaceutical industry¹
• HeadquartersStockholm¹
• Websitewww.sobi.com

See how the biggest companies compare on our leaderboards

Sobi - Swedish Orphan Biovitrum AB is an international biopharmaceutical company focused on rare diseases. The company develops, commercializes, and delivers therapies in the fields of haematology, immunology and specialty care.²

Corporate structure

Swedish Orphan Biovitrum sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Products and brands

• orphan drug

Listed on Wikidata.¹

Subsidiaries and ownership

Subsidiaries

• Swedish Orphan Biovitrum (Switzerland)

From Wikidata.¹

Acquisitions

1. Succeeded Biovitrum¹

Timeline

1. 2010Founded Founded¹

Calendar

Drug trials and FDA: coming up

1. Nov 17, 2026Phase 4 trial readout expected Phase 4 trial of Efanesoctocog alfa in Haemophilia A (Moderate or Severe): primary completion expected Nov 17, 2026 (ClinicalTrials.gov NCT06752850).⁴
2. Dec 30, 2026Phase 2 trial readout expected Phase 2 trial of Pacritinib in VEXAS: primary completion expected Dec 30, 2026 (ClinicalTrials.gov NCT06782373).⁵
3. Mar 2027Phase 3 trial readout expected Phase 3 trial of Efanesoctocog alfa in Haemophilia A (Moderate or Severe): primary completion expected Mar 2027 (ClinicalTrials.gov NCT06716814).⁶

Drug trials and FDA: recently

1. Jun 2, 2026Phase 3 trial completed Phase 3 trial of Efanesoctocog alfa in Hemophilia A, Severe: primary completion Jun 2, 2026, no results posted yet (ClinicalTrials.gov NCT05817812).⁷
2. Jun 30, 2024Phase 3 trial completed Phase 3 trial of Emapalumab in Macrophage Activation Syndrome: primary completion Jun 30, 2024, results posted Feb 19, 2026 (ClinicalTrials.gov NCT05001737).⁸
3. Jan 10, 2023Phase 3 trial completed Phase 3 trial of SEL-212 low-dose and SEL-212 high-dose in Chronic Gout: primary completion Jan 10, 2023, results posted Dec 3, 2025 (ClinicalTrials.gov NCT04596540).⁹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Links

• Websitewww.sobi.com¹
• WikipediaSwedish Orphan Biovitrum
• WikidataQ7654795